Genmab — Februar 2025
-
-
Jan -I mean as per the contract, yes, we can develop the molecule of cells if the J&J would decide not to opt in but not any indications where daratumumab is on the market or where it's in late-stage clinical development. That means other indications in multiple myeloma. There's still some areas left where daratumumab doesn't work or stopped working. We can potentially think about other cancers like AML, diffuse line banner, where we have seen some very good preclinical data with this molecule.
-
Another potential is solid tumors book.
And the reason that I mentioned that, James, is that the antibody, which is part of HexaBody-CD38 is a very good block of the ecto-enzymatic activity of the CD38 molecule, which is involved in the creation of adenosine. Adenosine is an immunosuppressive molecule. So potentially, this antibody is much better immune activator than daratumumab. It could be a key reason to use it in combination with checkpoint targeted molecules based on preclinical data. -
Finally, this could be a molecule which is of important for treatment of I&I or autoimmune diseases and inflammatory diseases because of the that daratumumab is known to be actually pretty active in some of the inflammatory diseases. But this is all speculation, let's first wait on the J&J optinn
decision. -
Q Would you be in a position to say, right, we're really like taking this into clinical development or would it more be we now need to do some very early exploratory trials because you just don't know that much yet about how well it would work, say, outside the DARZALEX indications?
-
Jan You definitely need to look at safety and you probably need a subcutaneous formulation, I think, for many of these indications because what you see the trend is with antibody medicines that more and more of them are formulated formulations and definitely in multiple myeloma that is the situation. But also, of course, in automimmune
diseases. I mean, and that needs to be a next step, I think, once you decide on developing that program. -
For Genmab, James, to be very honest, we need to, I think, under that scenario I would say, let's park it for now. But under that scenario, we would have to balance that with other programs we have in our own pipeline, which we already own 100% and we need to balance that.
-
not just on GEN1042 lahn, from Q3 24
". And then at some point, we may actually also begin to combine some of the immune activator programs like the acasunlimab program with ADCs because we think it makes perfect sense conceptually to start combining those." -
Not an easy target apparently
...: Pfizer drops its B7-H4 conjugate https://www.oncologypipeline.com/apexonco/pfizer-drops-its-b7-h4-conjugate -
InSysBio news
@insysbio
·
26 m
February 4 is #WorldCancerDay. In this regard we would like to share the poster developed in collaboration with Genmab and BioNTech SE. Our latest posters https://x.com/insysbio/status/1886800901777555929
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind